Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer.

James T. Symanowski,E. Kutarska,Mariusz Bidziński,Binh Nguyen,Reshma A. Rangwala,R. Wendel Naumann

Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer.

2013

James T. Symanowski
E. Kutarska
Mariusz Bidziński
Binh Nguyen
Reshma A. Rangwala
R. Wendel Naumann

5572 Background: Vintafolide (EC145), a folic acid/desacetylvinblastine conjugate, binds with high affinity to folate receptors expressed in epithelial ovarian cancers. This analysis evaluated the ...

Keywords:

Pathology
Pegylated Liposomal Doxorubicin
Vintafolide
Ovarian cancer
Adverse effect
Oncology
Internal medicine
Medicine
platinum resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations